Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;48(9):5356-5366.
doi: 10.1002/mp.15097. Epub 2021 Jul 29.

Proton range uncertainty reduction benefits for skull base tumors in terms of normal tissue complication probability (NTCP) and healthy tissue doses

Sebastian Tattenberg  1   2 , Thomas M Madden  2 , Bram L Gorissen  3 , Thomas Bortfeld  2 , Katia Parodi  1 , Joost Verburg  2
Affiliations

Proton range uncertainty reduction benefits for skull base tumors in terms of normal tissue complication probability (NTCP) and healthy tissue doses

Sebastian Tattenberg et al. Med Phys. 2021 Sep.

Abstract

Purpose: Proton therapy allows for more conformal dose distributions and lower organ at risk and healthy tissue doses than conventional photon-based radiotherapy, but uncertainties in the proton range currently prevent proton therapy from making full use of these advantages. Numerous developments therefore aim to reduce such range uncertainties. In this work, we quantify the benefits of reductions in range uncertainty for treatments of skull base tumors.

Methods: The study encompassed 10 skull base patients with clival tumors. For every patient, six treatment plans robust to setup errors of 2 mm and range errors from 0% to 5% were created. The determined metrics included the brainstem and optic chiasm normal tissue complication probability (NTCP) with the endpoints of necrosis and blindness, respectively, as well as the healthy tissue volume receiving at least 70% of the prescription dose.

Results: A range uncertainty reduction from the current level of 4% to a potentially achievable level of 1% reduced the probability of brainstem necrosis by up to 1.3 percentage points in the nominal scenario in which neither setup nor range errors occur and by up to 2.9 percentage points in the worst-case scenario. Such a range uncertainty reduction also reduced the optic chiasm NTCP with the endpoint of blindness by up to 0.9 percentage points in the nominal scenario and by up to 2.2 percentage points in the worst-case scenario. The decrease in the healthy tissue volume receiving at least 70% of the prescription dose ranged from -7.8 to 24.1 cc in the nominal scenario and from -3.4 to 38.4 cc in the worst-case scenario.

Conclusion: The benefits quantified as part of this study serve as a guideline of the OAR and healthy tissue dose benefits that range monitoring techniques may be able to achieve. Benefits were observed between all levels of range uncertainty. Even smaller range uncertainty reductions may therefore be beneficial.

Keywords: IMPT; proton therapy; range uncertainty; robust optimization.

PubMed Disclaimer

References

REFERENCES

    1. Mohan R, Grosshans D. Proton therapy - present and future. Adv Drug Deliv Rev. 2017;109:26-44.
    1. Wilson R. Radiological use of fast protons. Radiology. 1946;47(5):487-491.
    1. Paganetti H. Range uncertainties in proton therapy and Monte Carlo simulations. Phys Med Biol. 2012;57(11):R99-R117.
    1. Pflugfelder D, Wilkens J, Oelfke U. Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy. Phys Med Biol. 2008;53(6):1689-1700.
    1. Unkelbach J, Bortfeld T, Martin B, Soukup M. Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning. Med Phys. 2009;36(1):149-163.

LinkOut - more resources